Efficacy and safety profiles are considerations when moving from acute to chronic treatment for schizophrenia

At ECNP 2022, Professor Christoph Correll chatted about how both efficacy and safety profiles are important when choosing a medication in the acute phases of schizophrenia. However, as it is likely that the first medication choice for a patient with schizophrenia is the one they will remain on once stabilised, it’s important to choose one that can be used long-term and also review the choice once a patient is stable. Professor Correll also discussed how the relationship between plasma levels of an antipsychotic, it’s clinical efficacy and safety are not always linear and may depend on the individual patient. The high peak/trough variability with oral medications may be avoided by using a long-acting injectable antipsychotic. Such medications can also aid adherence.